177 related articles for article (PubMed ID: 38285120)
1. STAT6 mutations enriched at diffuse large B-cell lymphoma relapse reshape the tumor microenvironment.
Benoit A; Abraham MJ; Li S; Kim J; Estrada-Tejedor R; Bakadlag R; Subramaniam N; Makhani K; Guilbert C; Tu R; Salaciak M; Klein KO; Coyle KM; Hilton LK; Santiago R; Dmitrienko S; Assouline S; Morin RD; Del Rincon SV; Johnson NA; Mann KK
Int J Hematol; 2024 Mar; 119(3):275-290. PubMed ID: 38285120
[TBL] [Abstract][Full Text] [Related]
2. Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas.
Morin RD; Assouline S; Alcaide M; Mohajeri A; Johnston RL; Chong L; Grewal J; Yu S; Fornika D; Bushell K; Nielsen TH; Petrogiannis-Haliotis T; Crump M; Tosikyan A; Grande BM; MacDonald D; Rousseau C; Bayat M; Sesques P; Froment R; Albuquerque M; Monczak Y; Oros KK; Greenwood C; Riazalhosseini Y; Arseneault M; Camlioglu E; Constantin A; Pan-Hammarstrom Q; Peng R; Mann KK; Johnson NA
Clin Cancer Res; 2016 May; 22(9):2290-300. PubMed ID: 26647218
[TBL] [Abstract][Full Text] [Related]
3. T-cell protein tyrosine phosphatase, distinctively expressed in activated-B-cell-like diffuse large B-cell lymphomas, is the nuclear phosphatase of STAT6.
Lu X; Chen J; Sasmono RT; Hsi ED; Sarosiek KA; Tiganis T; Lossos IS
Mol Cell Biol; 2007 Mar; 27(6):2166-79. PubMed ID: 17210636
[TBL] [Abstract][Full Text] [Related]
4. Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas.
Lu X; Nechushtan H; Ding F; Rosado MF; Singal R; Alizadeh AA; Lossos IS
Blood; 2005 Apr; 105(7):2924-32. PubMed ID: 15591113
[TBL] [Abstract][Full Text] [Related]
5. Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma.
Guiter C; Dusanter-Fourt I; Copie-Bergman C; Boulland ML; Le Gouvello S; Gaulard P; Leroy K; Castellano F
Blood; 2004 Jul; 104(2):543-9. PubMed ID: 15044251
[TBL] [Abstract][Full Text] [Related]
6. Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma.
Ritz O; Guiter C; Castellano F; Dorsch K; Melzner J; Jais JP; Dubois G; Gaulard P; Möller P; Leroy K
Blood; 2009 Aug; 114(6):1236-42. PubMed ID: 19423726
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-4 induction of the CC chemokine TARC (CCL17) in murine macrophages is mediated by multiple STAT6 sites in the TARC gene promoter.
Liddiard K; Welch JS; Lozach J; Heinz S; Glass CK; Greaves DR
BMC Mol Biol; 2006 Nov; 7():45. PubMed ID: 17134490
[TBL] [Abstract][Full Text] [Related]
8. IL-4 induces expression of TARC/CCL17 via two STAT6 binding sites.
Wirnsberger G; Hebenstreit D; Posselt G; Horejs-Hoeck J; Duschl A
Eur J Immunol; 2006 Jul; 36(7):1882-91. PubMed ID: 16810739
[TBL] [Abstract][Full Text] [Related]
9. PTP1B is a negative regulator of interleukin 4-induced STAT6 signaling.
Lu X; Malumbres R; Shields B; Jiang X; Sarosiek KA; Natkunam Y; Tiganis T; Lossos IS
Blood; 2008 Nov; 112(10):4098-108. PubMed ID: 18716132
[TBL] [Abstract][Full Text] [Related]
10. Activating STAT6 mutations in follicular lymphoma.
Yildiz M; Li H; Bernard D; Amin NA; Ouillette P; Jones S; Saiya-Cork K; Parkin B; Jacobi K; Shedden K; Wang S; Chang AE; Kaminski MS; Malek SN
Blood; 2015 Jan; 125(4):668-79. PubMed ID: 25428220
[TBL] [Abstract][Full Text] [Related]
11. STAT6 is a cargo of exportin 1: Biological relevance in primary mediastinal B-cell lymphoma.
Miloudi H; Leroy K; Jardin F; Sola B
Cell Signal; 2018 Jun; 46():76-82. PubMed ID: 29501729
[TBL] [Abstract][Full Text] [Related]
12. PARP14 is a novel target in STAT6 mutant follicular lymphoma.
Mentz M; Keay W; Strobl CD; Antoniolli M; Adolph L; Heide M; Lechner A; Haebe S; Osterode E; Kridel R; Ziegenhain C; Wange LE; Hildebrand JA; Shree T; Silkenstedt E; Staiger AM; Ott G; Horn H; Szczepanowski M; Richter J; Levy R; Rosenwald A; Enard W; Zimber-Strobl U; von Bergwelt-Baildon M; Hiddemann W; Klapper W; Schmidt-Supprian M; Rudelius M; Bararia D; Passerini V; Weigert O
Leukemia; 2022 Sep; 36(9):2281-2292. PubMed ID: 35851155
[TBL] [Abstract][Full Text] [Related]
13. Autosomal Dominant STAT6 Gain of Function Causes Severe Atopy Associated with Lymphoma.
Minskaia E; Maimaris J; Jenkins P; Albuquerque AS; Hong Y; Eleftheriou D; Gilmour KC; Grace R; Moreira F; Grimbacher B; ; Morris EC; Burns SO
J Clin Immunol; 2023 Oct; 43(7):1611-1622. PubMed ID: 37316763
[TBL] [Abstract][Full Text] [Related]
14. Molecular complexity of diffuse large B-cell lymphoma: a molecular perspective and therapeutic implications.
Almasmoum HA
J Appl Genet; 2024 Feb; 65(1):57-72. PubMed ID: 38001281
[TBL] [Abstract][Full Text] [Related]
15. Mutated RAS-associating proteins and ERK activation in relapse/refractory diffuse large B cell lymphoma.
Benoit A; Bou-Petit E; Chou H; Lu M; Guilbert C; Luo VM; Assouline S; Morin RD; Dmitrienko S; Estrada-Tejedor R; Johnson NA; Mann KK
Sci Rep; 2022 Jan; 12(1):779. PubMed ID: 35039569
[TBL] [Abstract][Full Text] [Related]
16. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
Camicia R; Winkler HC; Hassa PO
Mol Cancer; 2015 Dec; 14():207. PubMed ID: 26654227
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic Mutations and Tumor Microenvironment Alterations of Older Patients With Diffuse Large B-Cell Lymphoma.
Zhu Y; Fu D; Shi Q; Shi Z; Dong L; Yi H; Liu Z; Feng Y; Liu Q; Fang H; Cheng S; Wang L; Tian Q; Xu P; Zhao W
Front Immunol; 2022; 13():842439. PubMed ID: 35401516
[TBL] [Abstract][Full Text] [Related]
18. Immune microenvironment-related gene mapping predicts immunochemotherapy response and prognosis in diffuse large B-cell lymphoma.
Chen W; Liang W; He Y; Liu C; Chen H; Lv P; Yao Y; Zhou H
Med Oncol; 2022 Jan; 39(4):44. PubMed ID: 35092504
[TBL] [Abstract][Full Text] [Related]
19. CCL8 as a promising prognostic factor in diffuse large B-cell lymphoma
Lou X; Zhao K; Xu J; Shuai L; Niu H; Cao Z; Wang J; Zhang Y
Front Immunol; 2022; 13():950213. PubMed ID: 36072582
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus (EBV) provides survival factors to EBV
Wu L; Ehlin-Henriksson B; Zhou X; Zhu H; Ernberg I; Kis LL; Klein G
Immunology; 2017 Dec; 152(4):562-573. PubMed ID: 28699226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
